Baker Bros. Advisors released its 13F for the quarter ended Sept. 30, 2018. Below is a summary:New Stakes
Aquestive ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

13Fs Hedge Funds

Seattle Genetics (SGEN) Reports FDA Approval of ADCETRIS (Brentuximab Vedotin) in Combination with ChemotherapyNovember 16, 2018 10:53 AM BioCryst Pharma (BCRX) Reports Data Highlighting the Rapid & Sustained Plasma Concentrations of BCX7353 in HAE PatientsNovember 16, 2018 7:10 AM BeiGene (BGNE) Reports Preliminary Clinical Data on PARP Inhibitor PamiparibNovember 16, 2018 7:05 AM DBV Technologies (DBVT) Announces Daniel Tasse as New CEONovember 16, 2018 6:08 AM Syros Pharmaceuticals (SYRS) Highlights Dose Escalation Data from Phase 1 Trial of SY-1365 Demonstrating Proof-of-MechanismNovember 15, 2018 9:31 AM Ra Pharmaceuticals (RARX) Reports Election of Bo Cumbo to BoardNovember 15, 2018 7:35 AM